Display options
Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2021). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2021): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Philippe A Cassier, Clémentine Peyramaure, Valery Attignon, Lauriane Eberst, Camille Pacaud, Sandrine Boyault, Françoise Desseigne, Mathieu Sarabi, Pierre Guibert, Pauline Rochefort, Nathalie Marques, Michel Rivoire, Aurélien Dupré, Patrice Peyrat, Catherine Terret, Isabelle Ray-Coquard, Clélia Coutzac, David Pérol, Jean-Yves Blay, Olivier Trédan, Christelle de la Fouchardière

Affiliations

  1. Département de Cancérologie Médicale, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France. Electronic address: [email protected].
  2. Service d'Oncologie, Centre Hospitalier Universitaire de Limoges, Limoges, France.
  3. Département de la Recherche Translationelle et de l'Innovation, Centre Léon Bérard, Lyon, France.
  4. Institut de Cancérologie de Strasbourg, Strasbourg, France.
  5. Service d'Onco-Hémato Pédiatrie, Hôpital Hautepierre, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.
  6. Département de Cancérologie Médicale, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France.
  7. Département de Chirurgie, Centre Léon Bérard, Lyon, France.
  8. Département de Cancérologie Médicale, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France; Université Claude Bernard Lyon I, Lyon, France.
  9. Direction de la Recherche Clinique et de l'Innovation, Centre Léon Bérard, Lyon, France.
  10. Département de Cancérologie Médicale, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France; Université Claude Bernard Lyon I, Lyon, France; Unicancer, Paris, France.

PMID: 34794033 PMCID: PMC8605190 DOI: 10.1016/j.tranon.2021.101266

Abstract

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.

METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the ProfiLER program.

RESULTS: Adenocarcinoma (n = 86, 59%), signet-cell (n = 37, 25%) and squamous-cell (n = 21, 14%) were the dominant histology amongst 147 patients. Genomic analyses could be performed for 114 (78%) patients. The most common genomic alterations involved ERBB2 (15%), KRAS (12%), CCND1 (7%), FGFR1-3 (8%), EGFR (5%) and MET (3%), TP53 (51%) and CDKN2A/B (10%). ERBB2, MET and FGFR alterations were found exclusively in the adenocarcinoma and signet-cell subtypes, while CCND1 amplification, TP53 mutations and CDKN2A/B loss were found in both adenocarcinoma and squamous-cell subtypes. Nine patients (8%) received therapy matched to their genomic alteration, with 5 of them achieving disease control. In an exploratory analysis, patients with stage IV disease at diagnosis who had an actionable alteration had longer overall survival compared to those without.

CONCLUSION: Genomic profiling for patients with advanced gastroesophageal cancers allows the identification of actionable alterations in large proportion of patients. Increased accessibility to molecularly matched therapy may improve survival in this disease.

Copyright © 2021. Published by Elsevier Inc.

Keywords: CGH; Gastric cancer; Molecular alterations, molecular-targeted agents; NGS; Oesophageal cancer

Publication Types